Kailera Therapeutics (NASDAQ:KLRA) Lowered to “Sell” Rating by Wall Street Zen

Kailera Therapeutics (NASDAQ:KLRA) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

KLRA has been the subject of several other reports. Leerink Partners assumed coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They issued an “outperform” rating and a $36.00 price objective for the company. TD Cowen assumed coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They issued a “buy” rating and a $57.00 price objective for the company. Evercore assumed coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They issued an “outperform” rating for the company. Zacks Research upgraded shares of Kailera Therapeutics to a “hold” rating in a report on Wednesday, May 13th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They issued an “overweight” rating and a $30.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $42.75.

Kailera Therapeutics Trading Up 0.2%

Shares of KLRA opened at $22.99 on Friday. Kailera Therapeutics has a one year low of $19.01 and a one year high of $28.23.

Insider Activity

In other Kailera Therapeutics news, Director Andrew T. Kaplan bought 8,398,438 shares of the stock in a transaction dated Monday, April 20th. The stock was purchased at an average cost of $16.00 per share, for a total transaction of $134,375,008.00. Following the completion of the acquisition, the director owned 26,255,581 shares of the company’s stock, valued at approximately $420,089,296. This trade represents a 47.03% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Rtw Investments, Lp bought 500,000 shares of the stock in a transaction dated Monday, April 20th. The shares were acquired at an average price of $16.00 per share, with a total value of $8,000,000.00. Following the completion of the acquisition, the insider directly owned 10,776,820 shares of the company’s stock, valued at approximately $172,429,120. The trade was a 4.87% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders acquired 10,460,938 shares of company stock worth $167,375,008.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.